Quarterly report [Sections 13 or 15(d)]

Related Party Transactions (Tables)

v3.26.1
Related Party Transactions (Tables)
6 Months Ended
Jun. 30, 2026
Related Party Transactions  
Schedule of effective date and PIK dividend or equity fee payable

​

​

​

​

​

​

​

​

​

​

​

​

PIK Dividend as

​

​

​

​

​

​

a % of fully

​

​

​

​

​

​

diluted

​

​

​

​

​

​

outstanding

​

Class of Stock

Partner Company/Subsidiary

  ​ ​ ​

Effective Date 1

  ​ ​ ​

capitalization

  ​ ​ ​

Issued

Avenue

​

February 17, 2015

 

2.5

%

Common Stock

Cellvation

​

October 31, 2016

 

2.5

%  

Common Stock

Checkpoint

​

March 17, 2015

 

—

%2  

Common Stock

Cyprium

​

March 13, 2017

 

2.5

%  

Common Stock

Helocyte

​

March 20, 2015

 

2.5

%  

Common Stock

LemmaTx

​

February 11, 2026 3

 

2.5

%  

Common Stock

Mustang

​

March 13, 2015

 

2.5

%  

Common Stock

Oncogenuity

​

April 22, 2020 3

​

2.5

%

Common Stock

Urica

​

November 7, 2017 3

 

2.5

%  

Common Stock

​

Note 1:

Represents the effective date of the Founders Agreement of each subsidiary/partner company. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year.

Note 2:

Instead of a PIK dividend, Checkpoint paid the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization. Due to the deconsolidation of Checkpoint in May 2025 related to the Sun Pharma transaction (see Note 3), Checkpoint no longer has this obligation to the Company.

Note 3:

Represents the Trigger Date, the date that the Fortress partner company/subsidiary first acquires, whether by license or otherwise, ownership rights in a product.

Schedule of effective date and annual consulting fee payable by the subsidiary to the Company

​

​

​

​

​

​

​

​

​

​

​

​

​

Partner Company/Subsidiary

  ​ ​ ​

Effective Date

  ​ ​ ​

Annual MSA Fee (Income)/Expense

​

Avenue

​

February 17, 2015

​

$

500

​

Cellvation

​

October 31, 2016

​

 

500

​

Checkpoint1

​

March 17, 2015

​

 

0

​

Cyprium

​

March 13, 2017

​

 

500

​

Helocyte

​

March 20, 2015

​

​

500

​

LemmaTx2

​

February 11, 2026

​

​

442

​

Mustang

​

March 13, 2015

​

 

500

​

Oncogenuity

​

February 10, 2017

​

​

500

​

Urica

​

November 7, 2017

​

​

500

​

Fortress

​

​

​

 

(3,942)

​

Consolidated (Income)/Expense

​

​

​

$

—

​

Note 1:Checkpoint was acquired by Sun Pharma in May 2025 (see Note 3).

Note 2:LemmaTx’s MSA fee for the year ended December 31, 2026 is pro-rated for the 2026 effective date of its MSA.